Panbela Provides Business Update and Reports Q3 2024

2 days ago · Panbela Provides Business Update and Reports Q3 2024 Financial Results November 14, 2024 16:10 ET | Source: Panbela Therapeutics, Inc. Panbela Therapeutics, Inc.

CouponFollow Extension

$12
OFF

Panbela Provides Business Update And Reports Q3 2024 Financial …

1 week from now

2 days ago · Up to $12.0 million financing commitment secured from strategic investor, Nant Capital. First patient enrolled in a Phase I dose escalation study to evaluate CPP-1X-S in …

nasdaq.com

$7
OFF

Earnings Call: Panbela Therapeutics Q3 2024 Financial Review

1 week from now

2 days ago · The company reported a Q3 2024 net loss of $7.2 million, with $142,000 in cash reserves. General and administrative expenses remained flat, while R&D expenses decreased …

investing.com

$12
OFF

Panbela Provides Business Update And Reports Q3 2024 Financial …

1 week from now

Panbela Therapeutics reports Q3 2024 financial results, securing $12.0 million from Nant Capital and enrolling the first patient in a Phase I study for CPP-1X-S in STK11 mutant NSCLC. The …

medpath.com

$39
OFF

Panbela Provides Business Update And Reports Q4 And FY 2024 …

1 week from now

Mar 26, 2024 · Financial / Business In aggregate, closed $39.1 million gross proceeds from equity during 2023 and Q1 2024 Validation of European Patent for Claims of a Novel Process for the …

yahoo.com

$1
OFF

Panbela Provides Business Update And Reports Q1 2024 Financial …

1 week from now

May 15, 2024 · First Quarter ended March 31, 2024 Financial Results General and administrative expenses were approximately $1.2 million in the quarter, compared to $1.4 million in the same …

businessinsider.com

42%
OFF

TriSalus Reports Q3 2024 Financial Results And Provides Business Update ...

1 week from now

2 days ago · Financial Results for Q3 2024. Revenue, all from the sale of the TriNav system, was $7.3 million and $21.2 million, respectively, for the three and nine months ended September 30, 2024. These were up 42% and 66%, respectively, compared to the same periods in 2023.

biospace.com

$1
OFF

Panbela Provides Business Update And Reports Q3 2024 Financial …

1 week from now

2 days ago · Third Quarter ended September 30, 2024 Financial Results General and administrative expenses were approximately $1.1 million in the quarter, nearly flat compared …

einnews.com

$12
OFF

Panbela Provides Business Update And Reports Q3 2024 …

1 week from now

with urgent unmet medical needs, today provides a business update and reports ﬁnancial results for the quarter ended September 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q3 2024 and Recent Highlights: • Up to $12.0 million ﬁnancing commitment secured from strategic investor, Nant Capital.

panbela.com

$1
OFF

Panbela Provides Business Update And Reports Q3 2022 Financial …

1 week from now

Nov 10, 2022 · Story continues. Third quarter ended September 30, 2022 Financial Results. General and administrative expenses were $1.3 million in the third quarter of 2022, compared …

yahoo.com

$1
OFF

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial …

1 week from now

5 days ago · Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update ... Net Sales of $1.7 Million in Q3 2024. Conference Call and Webcast at 5:00pm ET.

morningstar.com

$7
OFF

TriSalus Reports Q3 2024 Financial Results And Provides Business …

1 week from now

3 days ago · Financial Results for Q3 2024 Revenue, all from the sale of the TriNav system, was $7.3 million and $21.2 million , respectively, for the three and nine months ended September …

nasdaq.com

$7
OFF

Movano Health Reports Q3 2024 Financial Results And Provides …

1 week from now

3 days ago · The Company reported an operating loss of $7.4 million in Q3 2024, compared to an operating loss of $9.1 million in Q3 2023. Total cash and cash equivalents at September 30, …

victoriaadvocate.com

FAQs about Panbela Provides Business Update and Reports Q3 2024 Coupon?

Who is panbela Therapeutics?

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. Panbela’s lead assets are Ivospemin (SBP-101) and Flynpovi. ...

What was the net loss in Q1 2024?

Net loss in the quarter was approximately $7.2 million, or $1.48 per diluted share, compared to a net loss of $7.8 million, or $53.74 per diluted share, in the same period last year. Total cash was $142,000 as of September 30, 2024. ...

How much did research and development expenses increase in Q3 2024?

Upcoming Milestones Q3 2024 Financial Results Research and development expenses increased by $0.3 million to $2.6 million for the three months ended September 30, 2024, as compared to $2.3 million for the three months ended September 30, 2023. ...

How much did CPP pay a note holder in 2024?

Notes payable, plus accrued interest, on the balance sheet, the result of the acquisition of CPP, totaled approximately $4.2 million. The current portion of the notes payable plus accrued interest totaled approximately $1.3 million and was paid to the noteholder in the first quarter of 2024. ...